Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation-Reference-Cited by-同舟云学术

Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation

Published:2020-12-09 Issue:2 Volume:25 Page:729-741
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Cuijpers Ilona¹²^ORCID,Papageorgiou Anna‐Pia¹²,Carai Paolo¹,Herwig Melissa³⁴⁵,Mügge Andreas³⁴,Klein Thomas⁶,Hamdani Nazha³⁴⁵⁷,Jones Elizabeth A. V.¹²,Heymans Stephane¹²⁸

Affiliation:

1. Center for Molecular and Vascular Biology KU Leuven Leuven Belgium

2. Department of Cardiology CARIM School for Cardiovascular Diseases Maastricht University Medical Center Maastricht The Netherlands

3. Molecular Cardiology and Experimental Cardiology Ruhr University Bochum Bochum Germany

4. Department of Cardiology St. Josef‐Hospital Ruhr University Bochum Bochum Germany

5. Institute of Physiology Ruhr University Bochum Bochum Germany

6. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

7. Department of Clinical Pharmacology Ruhr University Bochum Bochum Germany

8. Holland Heart House ICIN‐Netherlands Heart Institute Utrecht The Netherlands

Funder

Fonds Wetenschappelijk Onderzoek

Deutsche Forschungsgemeinschaft

Innovative Medicines Initiative

Stichting voor de Technische Wetenschappen

Hartstichting

Boehringer Ingelheim

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.16122

Reference52 articles.

1. Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure–volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort

2. Diastolic Stiffness of the Failing Diabetic Heart

3. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction

4. Obese patients have higher circulating protein levels of dipeptidyl peptidase IV

5. High circulating plasma dipeptidyl peptidase‐ 4 levels in non‐obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL‐C levels, triceps skinfolds, total intra‐abdominal adipose tissue volume and presence of diabetes: a case‐control study;Anoop S;BMJ Open Diabetes Res Care,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress;Frontiers in Pharmacology;2023-11-09

2. Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis;Journal of Diabetes Investigation;2023-04-24

3. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis;British Journal of Pharmacology;2022-11

4. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms;Naunyn-Schmiedeberg's Archives of Pharmacology;2022-08-10

5. Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats;Journal of the American Heart Association;2022-08-02